US ovarian cancer mortality declined from 1999 to 2020, but significant disparities remain among older women, non-Hispanic White women, and those living in rural areas, as well as in the Northeastern ...

University of Kentucky Markey Cancer Center researchers have identified a protein that could be a promising treatment target ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are ...

Former Philadelphia Eagles player Bryan Braman, who won a Super Bowl, has died. He was 38 years old.

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves - insights that could help researchers develop more effective treatment strategies.

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights that could help researchers develop more effective treatment strategies.

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Corcept is developing relacorilant in ovarian cancer and a variety of other serious disorders, including endogenous hypercortisolism and prostate cancer. Relacorilant is proprietary to Corcept and is ...